Annual report pursuant to Section 13 and 15(d)

Note 13 - Notes Payable (Details Textual)

v3.8.0.1
Note 13 - Notes Payable (Details Textual)
1 Months Ended 8 Months Ended 12 Months Ended
Jan. 16, 2018
USD ($)
Nov. 02, 2017
USD ($)
Mar. 31, 2017
USD ($)
Mar. 03, 2017
USD ($)
Mar. 01, 2017
USD ($)
Jul. 01, 2016
Jun. 22, 2016
USD ($)
May 31, 2016
USD ($)
shares
Mar. 31, 2014
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
Nov. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2016
USD ($)
shares
Jul. 31, 2015
USD ($)
May 31, 2015
USD ($)
$ / shares
Mar. 31, 2014
USD ($)
$ / shares
shares
Jun. 30, 2013
USD ($)
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Jun. 25, 2013
USD ($)
Feb. 28, 2017
Jul. 31, 2014
USD ($)
Jul. 31, 2012
USD ($)
Repayments of Notes Payable                                     $ 59,753,740 $ 231,453 $ 30,333,333            
Change in Fair Value of Financial Instruments                                     153,357 2,858,524 (614,782)            
Interest Payable, Current                     $ 5,756,519             5,756,519              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                   $ 1.19                 $ 1.19                
Equity Method Investment, Payment Upon Termination of Joint Venture                                     110,000            
Interest Expense, Debt                                     159,000 5,000 1,300,000            
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs                                     134,000   326,000            
Disposal Group, Including Discontinued Operation, Interest Expense                                     1,706,491 14,856,404 5,603,820            
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months                   $ 2,400,000                 $ 2,400,000                
R-NAV [Member]                                                      
Repayments of Notes Payable                         $ 333,333 $ 333,333                          
Debt Instrument, Face Amount                                                   $ 666,666  
Equity Method Investment, Payment Upon Termination of Joint Venture               $ 110,000         110,000                            
Equity Method Investment, Forgiven Promissory Note, Amount               $ 333,333         $ 333,333                            
R-NAV [Member] | Preferred Stock [Member]                                                      
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares               1,500,000         1,500,000                            
R-NAV [Member] | Common Stock [Member]                                                      
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares               3,500,000         3,500,000                            
Series KK Warrants [Member]                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                   $ 1.918                 $ 1.918                
Minimum [Member]                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                   0.01                 0.01                
Maximum [Member]                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                   $ 3.04                 $ 3.04                
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]                                                      
Loss Contingency, Damages Sought, Value   $ 1,914,827.22                                                  
CRG Loan Agreement, Ohio Case [Member]                                                      
Release of Cash Held in Escrow       $ 2,000,000                                              
CRG Loan Agreement, Texas Case [Member]                                                      
Release of Cash Held in Escrow       3,000,000                                              
CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member] | Subsequent Event [Member]                                                      
Loss Contingency, Damages Awarded,Value, Requested Modified Amount $ 2,900,000                                                    
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]                                                      
Loss Contingency, Damages Awarded, Value, Additional Amount       7,000,000           $ 7,000,000                                  
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration                   4,100,000                                  
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Subsequent Event [Member]                                                      
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration $ 4,100,000                                                    
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Maximum [Member]                                                      
Loss Contingency, Damages Awarded, Value       66,000,000           66,000,000                                  
Federal Funds Rate [Member] | R-NAV [Member]                                                      
Debt Instrument, Interest Rate, Stated Percentage                                                   0.31%  
Platinum-Montaur Life Sciences LLC Litigation [Member]                                                      
Line of Credit Facility, Maximum Borrowing Capacity                                                     $ 50,000,000
Line of Credit Facility, Current Borrowing Capacity                                 $ 35,000,000                   35,000,000
Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated                                                     15,000,000
Proceeds from Lines of Credit                                       0 4,500,000 $ 0 $ 4,000,000 $ 8,000,000      
Debt Instrument, Interest Rate, Stated Percentage                 10.00%           10.00% 10.00% 10.00%                    
InterestRateInAdditionToAmendedAgreement                                 0.125%                    
Percentage of VWAP for Conversion Calculation                                 90.00%                    
Period of Preceding Date of Conversion Request                                 10 days                    
Minimum Revenue from Sales and Licensing for Mandatory Repayment Due                                 $ 2,000,000                    
Repayments of Notes Payable                                 $ 4,800,000                    
Stock for Stock Conversion Number of Shares Converted | shares                                 2,364.9                    
Number of Common Shares Underlying Series B Preferred Stock | shares                                 7,733,223                    
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock | shares                                 3,270                    
Debt Instrument, Convertible, Threshold Trading Days                             10                        
Debt Instrument, Convertible, Stock Price Trigger | $ / shares                             $ 2.53                        
Embedded Derivative, Fair Value of Embedded Derivative Liability                       153,000               153,000              
Change in Fair Value of Financial Instruments                                       2,900,000 (615,000)            
Convertible Debt, Fair Value Disclosures                   2,000,000   9,600,000             $ 2,000,000 9,600,000              
Interest Expense, Debt, Excluding Amortization                                     265,000 1,000,000 761,000            
Line of Credit Facility, Decrease Forgiveness Interest Percentage           6.00%                                          
Platinum-Montaur Life Sciences LLC Litigation [Member] | Prime Rate [Member]                                                      
Debt Instrument, Basis Spread on Variable Rate                             6.75% 6.75% 6.75%                    
Platinum-Montaur Life Sciences LLC Litigation [Member] | Oxford Financing Rate [Member]                                                      
Debt Instrument, Basis Spread on Variable Rate                 0.125%                                    
Platinum-Montaur Life Sciences LLC Litigation [Member] | Interest Rate Pursuant to CRG Term Loan [Member]                                                      
Debt Instrument, Basis Spread on Variable Rate                             0.125%                        
Platinum Loan Agreement [Member] | PPCO [Member]                                                      
Line of Credit Facility, Maximum Borrowing Capacity                                                     $ 50,000,000
Embedded Derivative, Fair Value of Embedded Derivative Liability                   $ 0                 0                
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)                                     $ (153,000)                
Repayments of Debt       7,700,000                                              
Convertible Debt       1,900,000                                              
Term Loan Agreement [Member] | Cardinal Health 414 [Member]                                                      
Letters of Credit Outstanding, Amount       7,000,000                                              
Term Loan Agreement [Member] | CRG [Member]                                                      
Letters of Credit Outstanding, Amount       12,000,000                                              
Term Loan Agreement [Member] | CRG [Member]                                                      
Debt Instrument, Interest Rate, Stated Percentage                             14.00%                   14.00%    
Interest Expense, Debt, Excluding Amortization                                       553,000 1,300,000            
Repayments of Debt       59,000,000                                              
Debt Instrument, Face Amount                             $ 50,000,000                        
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions                             $ 10,000,000                        
Percentage of Per Annum Interest Paying in Cash                             10.00%                        
Percentage of Per Annum Interest as Compounded Interest                             4.00%                        
Debt Instrument, Number of Quarterly Payments                             8                        
Debt Instrument Payment Terms Payment Period                             2 years                        
Notes Payable                       51,700,000           $ 51,300,000   51,700,000 51,300,000            
Debt Instrument, Unamortized Discount (Premium), Net                             $ 2,200,000                        
Debt Instrument End of Term Fee, Amount                             1,000,000                        
Debt Instrument, Fee Amount                             1,000,000                        
Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum                             5,000,000                        
Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months                       22,500,000               22,500,000              
DebtInstrumentCovenantComplianceTargetRevenueMinimum                             $ 45,000,000                        
Debt Instrument, Covenant Compliance Cure Right Ratio                             2.5                        
Debt Instrument, Covenant Compliance Liquidity Minimum                             $ 5,000,000                        
Debt Instrument, Interest Rate in the Event of Default                             18.00%                        
Primary Bank Account Cash Taken Possession Of By Creditor             $ 4,100,000                                        
Payments to Prepayment Premium and Backend Facility Fee on Claims of Default             3,900,000                                        
Payments to Principal Balance of Debt on Claims of Default             $ 189,000                                        
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit       59,000,000                                              
Term Loan Agreement [Member] | CRG [Member] | Minimum [Member]                                                      
Debt Instrument, Agreed-upon Final Payoff Amount       47,000,000                                              
Term Loan Agreement [Member] | CRG [Member] | Maximum [Member]                                                      
Debt Instrument, Agreed-upon Final Payoff Amount       66,000,000                                              
Term Loan Agreement [Member] | CRG [Member] | Accrued Liabilities and Other [Member]                                                      
Interest Payable, Current                       $ 5,800,000           0   $ 5,800,000 $ 0            
Term Loan Agreement [Member] | CRG [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]                                                      
Repayments of Debt     $ 59,000,000 $ 59,000,000 $ 59,000,000                                            
Oxford Finance, LLC [Member]                                                      
Debt Instrument, Interest Rate, Stated Percentage                 8.50%             8.50%                      
Debt Instrument, Face Amount                 $ 30,000,000             $ 30,000,000                      
Debt Instrument, Unamortized Discount (Premium), Net                 3,000,000             3,000,000                      
Debt Instrument End of Term Fee, Amount                                   $ 2,400,000                  
Repayments of Long-term Debt                             $ 31,700,000                        
Debt Instrument, Early Redemption Fee Amount                             $ 289,000                        
Oxford Finance, LLC [Member] | Series KK Warrants [Member]                                                      
Debt Instrument, Unamortized Discount (Premium), Net                 $ 120,000             $ 120,000                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares                 391,032             391,032                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                 $ 1.918             $ 1.918                      
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]                                                      
Debt Instrument, Interest Rate, Stated Percentage                     4.00% 8.99%               8.99%              
Debt Instrument, Face Amount                     $ 396,000 $ 348,000               $ 348,000              
Debt Instrument, Term                     10 years 240 days                              
Debt Instrument, Periodic Payment                     $ 40,000 $ 45,000